Showing 1 - 3 results of 3 for search 'Werner Engl', query time: 0.02s Refine Results
  1. 1
    Long-term adverse events, efficacy, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin in patients aged < 18 years with primary immunodeficiency diseases

    Long-term adverse events, efficacy, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin in patients aged < 18 years with primary... by Lina Laguado, Richard L. Wasserman, Isaac Melamed, Lisa Kobrynski, Sudhir Gupta, Werner Engl, Heinz Leibl, Leman Yel

    Published 2018-06-01
    Get full text
    Article
  2. 2
    Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: subanalysis of the randomized, phase 3 PROPEL study

    Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: subanalysis of the randomized, phase 3 P... by Carmen Escuriola-Ettingshausen, Robert Klamroth, Miguel Escobar, Oleksandra Stasyshyn, Srilatha Tangada, Werner Engl, Ivan Honauer, Hye-Youn Lee, Pratima Chowdary, Jerzy Windyga

    Published 2023-06-01
    Get full text
    Article
  3. 3
    Local adverse reaction rates decreased over time during treatment with recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin G (fSCIG) in patients with primary immunodeficiency diseases in the fSCIG phase 3 studies

    Local adverse reaction rates decreased over time during treatment with recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin G (fSCIG) in patients wit... by Lina Laguado, Mark Stein, Richard L. Wasserman, Isaac Melamed, Sudhir Gupta, Lisa Kobrynski, Arye Rubinstein, Christopher J. Rabbat, Werner Engl, Barbara McCoy, Heinz Leibl, Leman Yel

    Published 2018-06-01
    Get full text
    Article

Search Tools: